BioPharmSignal logoBioPharmSignal

Biotech News

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Candel Therapeutics (CADL)Candel Therapeutics2026-06-25 13:46 ESTEarnings

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Announced purpose-built commercial partnership with EVERSANA ® to support potential U.S.

Open original release

Related news

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics to Present at Upcoming Investor Conferences

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Announces Proposed $100 Million Public Offering

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Announces Pricing of Public Offering

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

View all latest news

Candel Therapeutics

Candel Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

CADLCandel Therapeutics2026-06-26 08:45 EST

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

CADLCandel Therapeutics2026-06-26 08:45 EST

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

CADLCandel Therapeutics2026-06-26 08:45 EST

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

CADLCandel Therapeutics2026-06-26 08:45 EST

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

CADLCandel Therapeutics2026-06-26 08:45 EST

Candel Therapeutics to Present at Upcoming Investor Conferences

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States